In the severe MASLD group, we observed a statistically significant higher predicted presence of succinate semialdehyde dehydrogenase, L-asparaginase beta-aspartyl peptidase, alanine dehydrogenase, aspartate carbamoyltransferase regulatory subunit, and alanine dehydrogenase (K19244), alongside a lower predicted presence of alanine dehydrogenase (K00259), glutamate dehydrogenase (NAD(P)+), and 1-pyrroline-5-carboxylate dehydrogenase (Figure 3a). This evidence concerns the gene CAD and metabolic dysfunction-associated steatotic liver disease.